Most U.S. Pharmacists Back Methadone in Pharmacies, Survey Finds

A nationwide survey of licensed pharmacists has found broad support for letting community pharmacies dispense methadone on behalf of opioid treatment programs, alongside a striking lack of awareness that federal rules already permit it. The study, led by Li-Tzy Wu of Duke University School of Medicine and published Monday in Addiction Science & Clinical Practice, surveyed 585 pharmacists across all 50 states and the District of Columbia.

Methadone remains the medication with the strongest evidence base for opioid use disorder, reducing illicit opioid use, overdose risk and mortality when taken consistently under supervision. But in the United States it is dispensed almost exclusively through specialized opioid treatment programs, or OTPs, that require most patients to travel to a clinic daily for observed dosing. Those clinics cluster in cities, leaving large rural stretches with no practical access to the drug.

One proposed fix is the pharmacy medication unit: a licensed pharmacy that partners with an OTP to administer or dispense methadone at its own counter while the treatment program retains medical responsibility for the patient. The arrangement is allowed under federal rules and has been used in other countries for decades, but it remains rare in the United States.

Willingness without readiness

The Duke-led team found a reservoir of professional goodwill. Of the pharmacists who completed the survey, 57.2 percent said they were confident in their ability to develop a partnership with an OTP to establish or join a pharmacy methadone medication unit, and 25.1 percent said they were likely to pursue such a partnership themselves. A further 39.2 percent believed most of their peers would be interested in participating.

That willingness ran up against a knowledge gap. Only 37.9 percent of respondents were aware that federal and state regulations already allow pharmacy-based methadone medication units, and just 6.2 percent had ever worked at an opioid treatment program. Pharmacists who do not know a practice exists are unlikely to train for it, advocate for it or negotiate the arrangements it requires, the authors write.

Who feels most prepared

The analysis found that confidence clustered among pharmacists with more autonomy and decision-making authority. Respondents who were pharmacy owners, partners or managers reported higher odds of feeling able to build an OTP partnership than staff pharmacists, as did those working at independent pharmacies rather than hospital or clinic pharmacies. Pharmacists practicing in the Western United States reported higher odds than those in the Northeast, and men reported higher odds than women. Similar patterns appeared for stated intention to participate.

The authors frame the practice-setting findings as a sign that institutional flexibility matters as much as individual attitude: pharmacists who can restructure workflows and take on new responsibilities were more inclined to embrace the model.

The barriers pharmacists named

Asked what would stand in the way, respondents pointed first to workload — methadone treatment typically requires daily dosing, a schedule that strains already busy community pharmacies. Regulatory complexity and liability exposure ranked close behind, followed by a lack of training specific to methadone dispensing and the needs of patients with opioid use disorder.

Those concerns are not incidental. Methadone has a narrow therapeutic window, and dispensing it safely requires familiarity with drug interactions, overdose risk and the clinical protocols that opioid treatment programs follow. Pharmacists accustomed to filling prescriptions for chronic conditions would need structured education and clear practice guidelines before taking on the responsibility.

What the study suggests

The benefits pharmacists identified were as concrete as the barriers: improved access to treatment, the ability to serve more patients, convenient locations and less stigma for people picking up medication at an ordinary pharmacy counter rather than a dedicated clinic.

The authors argue that the gap between support and readiness is a coordination problem rather than a rejection of the model. State pharmacy boards, pharmacist associations and opioid treatment authorities could work together to design workable programs and set guidelines and training requirements for pharmacies that want to participate, they write.

The study was supported by a grant from the National Institute on Drug Abuse. It joins a body of recent research and policy interest in loosening methadone's distribution bottleneck. A separate study published in the same journal in August documented the experience of a mobile methadone unit in Rhode Island, and Congress has cycled through proposals to expand where the medication can be dispensed, most recently through a revived version of the Modernizing Opioid Treatment Access Act.

The survey's authors note a limitation that applies to their design: pharmacists who chose to complete an online survey may differ from those who did not, and stated confidence is not the same as demonstrated capacity. The findings describe intent, not what a pharmacy methadone medication unit would look like in practice. Patients seeking medication-assisted treatment still obtain methadone the same way they did before the paper was published.